Journal: Scientific Reports

Article Title: Esketamine attenuates bone cancer pain by suppressing MAPK signaling and glial activation in the spinal dorsal horn of rats

doi: 10.1038/s41598-026-38137-y

Figure Lengend Snippet: ESK inhibits MAPK pathway activation in the SDH of BCP rats. ( A–D ) Representative WB images and quantification of phosphorylated JNK ( B ), p38 ( C ), and ERK ( D ) levels. Data are mean ± SEM of biological replicates n = 3. *** P < 0.001 versus sham plus vehicle group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus BCP plus vehicle group, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test. ( E ) Schematic of experimental timeline showing repeated intrathecal administration of ESK, SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) on POD 13 to 16. ( F ) Co-treatment with ESK enhanced the MAPK inhibitors induced increase in PWT after intrathecal administration. Notably, co-administration of MAPK inhibitors did not further enhance ESK’s analgesic effect, suggesting that its antinociceptive action mainly involves MAPK pathway inhibition. Data are mean ± SEM of biological replicates n = 7–8 rats/group. Two-way ANOVA with repeated measures followed by post hoc Tukey test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. BCP + DMSO; # P < 0.05, BCP + ESK+SB203580 vs. BCP + SB203580, BCP + ESK+SP600125 vs. BCP + SP600125 at corresponding time points. ( G ) Western blot of IL-1β, IL-6, and TNF-α expression in the SDH. ( H–J ) Quantification of cytokine levels showed further reductions in IL-1β ( H ), IL-6 ( I ), and TNF-α ( J ) with combined ESK and MAPK inhibitor treatment. Data are mean ± SEM of biological replicates n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001, ns, not significant. One-way ANOVA with repeated measures followed by post hoc Tukey test.

Article Snippet: To assess MAPK pathway involvement, the JNK inhibitor SP600125 (5 μg/10 μl; Cell Signaling Technology, USA) and the p38 inhibitor SB203580 (10 μg/10 μl; Abcam, UK) were dissolved in DMSO to a final DMSO concentration of 1%.

Techniques: Activation Assay, Inhibition, Western Blot, Expressing

Journal: Neuroscience Bulletin

Article Title: IL-33 Regulates the Phenotypic Transformation of Reactive Astrocytes via PENK-ERK/MAPK Pathway in Parkinson’s Disease

doi: 10.1007/s12264-025-01566-2

Figure Lengend Snippet: The role of PENK-ERK/MAPK pathway validated in vivo and in vitro . A, B Protein expression of p-ERK1/2 in astrocytes assessed by WB ( A ) and quantitative analyses ( B ) among groups, n = 3 per group; C, D Protein expression of p-ERK1/2 in the SN assessed by WB ( C ) and quantitative analyses (D) among groups, n = 3 per group; E Representative confocal images of p-ERK1/2 (red) and GFAP (green) in the SN, scale bar = 25 μm; F Quantification of p-ERK1/2 average intensity in groups, n = 4 per group; G Quantitative analysis of the ratio of p-ERK1/2 + GFAP + to GFAP + area in the SN, n = 4 per group; H Cell viability of MPP + - and U0126-treated astrocytes assessed by CCK-8; I–K Protein expression of C3 and S100A10 in astrocytes assessed by WB ( I ) and quantitative analyses ( J , K ) among groups, n = 3 per group; Significances were assessed using two-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Article Snippet: To investigate whether the ERK/MAPK pathway is involved, a specific MEK inhibitor (U0126, MCE) was employed.

Techniques: In Vivo, In Vitro, Expressing, CCK-8 Assay

Journal: American Journal of Translational Research

Article Title: Morinda officinalis polysaccharide enhances osteogenic differentiation and migration of bone marrow mesenchymal cells by activating P38MAPK signal transduction

doi: 10.62347/VVPN2529

Figure Lengend Snippet: Effects of MOP on MAPK signaling pathway. A. Phosphorylation of p38, ERK1/2, and JNK in BMSCs analyzed using western blotting. B. Quantitative results of ERK1/2 phosphorylation. C. Quantitative results of p38 phosphorylation. D. Quantitative results of JNK phosphorylation. * P <0.05, ** P <0.01.

Article Snippet: Once the monolayer of cells covered 90% of the bottom of the wells, the medium was replaced with fresh medium containing MOP (Shifengbio, Shanghai, China) or MOP combined with the p38 MAPK pathway inhibitor SB203580 (2 μg/mL, HY-10256, MedChemExpress, Monmouth Junction, NJ, USA), and incubated for 24 h [ 19 ].

Techniques: Phospho-proteomics, Western Blot

Journal: American Journal of Translational Research

Article Title: Morinda officinalis polysaccharide enhances osteogenic differentiation and migration of bone marrow mesenchymal cells by activating P38MAPK signal transduction

doi: 10.62347/VVPN2529

Figure Lengend Snippet: Effects of P38 MAPK signaling pathway inhibitor and MOP on MSC proliferation. A. BMSC viability evaluated using MTT assay. B, C. BMSC clone formation rate evaluated using colony formation experiment (10×, 200 μm). D, E. BMSC migration assessed using wound-healing assay. * P <0.05, ** P <0.01, *** P <0.001.

Article Snippet: Once the monolayer of cells covered 90% of the bottom of the wells, the medium was replaced with fresh medium containing MOP (Shifengbio, Shanghai, China) or MOP combined with the p38 MAPK pathway inhibitor SB203580 (2 μg/mL, HY-10256, MedChemExpress, Monmouth Junction, NJ, USA), and incubated for 24 h [ 19 ].

Techniques: MTT Assay, Migration, Wound Healing Assay

Journal: American Journal of Translational Research

Article Title: Morinda officinalis polysaccharide enhances osteogenic differentiation and migration of bone marrow mesenchymal cells by activating P38MAPK signal transduction

doi: 10.62347/VVPN2529

Figure Lengend Snippet: Effect of P38 MAPK signaling pathway inhibitor and MOP on BMSC osteogenic differentiation. A, B. Alizarin red staining for detection of calcium deposits (20×, 100 μm). C, D. Alkaline phosphatase (ALP) staining for detection of enzyme activity (20×, 100 μm). E-I. The protein expression levels of collagen I (Col I), osteocalcin (OCN), runt-related transcription factor 2 (RUNX2) and ALP levels examined using western blot. J-M. The mRNA expression levels of OCN, ALP, RUNX2, and Col I in BMSCs assessed using RT-qPCR. * P <0.05, ** P <0.01, *** P <0.001.

Article Snippet: Once the monolayer of cells covered 90% of the bottom of the wells, the medium was replaced with fresh medium containing MOP (Shifengbio, Shanghai, China) or MOP combined with the p38 MAPK pathway inhibitor SB203580 (2 μg/mL, HY-10256, MedChemExpress, Monmouth Junction, NJ, USA), and incubated for 24 h [ 19 ].

Techniques: Staining, Activity Assay, Expressing, Western Blot, Quantitative RT-PCR